This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control. The study is seeking for participants who: * Are confirmed to have NSCLC (Stage 3 or 4). * Have PD-L1 levels in more than 50% of the cancer cells. All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV)

Trial Details

NCT ID
NCT06758401
Phase
PHASE3
Sponsor
Pfizer
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Sigvotatug Vedotin
  • Pembrolizumab
Locations (sample)
  • Fullerton, California, United States|33.87029,-117.92534
  • Golden, Colorado, United States|39.75554,-105.2211
  • Grand Junction, Colorado, United States|39.06387,-108.55065
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Orange City, Florida, United States|28.94888,-81.29867

Key Eligibility Criteria

  • Participants must meet the following criteria:
  • Have pathologically confirmed Stage IIIB or IIIC NSCLC and not be a candidate for surgical resection or definitive chemoradiation, or Stage IV NSCL…
  • Participants with non-squamous histology must have documented negative test results for EGFR, ALK, and ROS1 AGAs and no known AGAs in NTRK, BRAF, R…
  • Large cell neuroendocrine carcinoma is excluded.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →